DPP4 deficiency preserves cardiac function via GLP-1 signaling in rats subjected to myocardial ischemia/reperfusion

Suppressive effects of glucagon-like peptide-1 on interferon-γ-induced nitric oxide production in insulinproducing cells is mediated by inhibition of tumor necrosis factor-α production

(2014) E. Hahm et al.   JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION

Exenatide Improves Glucose Homeostasis and Prolongs Survival in a Murine Model of Dilated Cardiomyopathy

(2011) Arpita Kalla Vyas et al.   PLoS One

Glucagon-Like Peptide-1 Increases Myocardial Glucose Uptake via p38α MAP Kinase–Mediated, Nitric Oxide–Dependent Mechanisms in Conscious Dogs With Dilated Cardiomyopathy

(2010) Siva Bhashyam et al.   Circulation-Heart Failure

Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4

(2010) M. Arakawa et al.   DIABETES

Genetic Deletion or Pharmacological Inhibition of Dipeptidyl Peptidase-4 Improves Cardiovascular Outcomes After Myocardial Infarction in Mice

(2010) M. Sauve et al.   DIABETES

Glucagon-Like Peptide (GLP)-1(9-36)Amide-Mediated Cytoprotection Is Blocked by Exendin(9-39) Yet Does Not Require the Known GLP-1 Receptor

(2010) Kiwon Ban et al.   ENDOCRINOLOGY

TNFα in myocardial ischemia/reperfusion, remodeling and heart failure

(2010) Petra Kleinbongard et al.   HEART FAILURE REVIEWS

GLP-1 signaling preserves cardiac function in endotoxemic Fischer 344 and DPP4-deficient rats

(2010) Hui-Chun Ku et al.   NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

Thaliporphine ameliorates cardiac depression in endotoxemic rats through attenuating TLR4 signaling in the downstream of TAK-1 phosphorylation and NF-κB signaling

(2010) Wen-Pin Chen et al.   NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

Glucagon-like peptide-1 (GLP-1) attenuates post-resuscitation myocardial microcirculatory dysfunction

(2010) Betsy B. Dokken et al.   RESUSCITATION

Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?

(2009) David J Grieve et al.   BRITISH JOURNAL OF PHARMACOLOGY

Synergy between CD26/DPP-IV Inhibition and G-CSF Improves Cardiac Function after Acute Myocardial Infarction

(2009) Marc-Michael Zaruba et al.   Cell Stem Cell

Role of Glycogen Synthase Kinase-3β in Cardioprotection

(2009) Magdalena Juhaszova et al.   CIRCULATION RESEARCH

Glucagon-like Peptide-1 and Myocardial Protection: More than Glycemic Control

(2009) Anjali V. Fields et al.   CLINICAL CARDIOLOGY

GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice

(2009) M. H. Noyan-Ashraf et al.   DIABETES

DPP4 Inhibitors: a new approach in diabetes treatment

(2008) John Doupis et al.   ADVANCES IN THERAPY

The malonyl CoA axis as a potential target for treating ischaemic heart disease

(2008) J. R. Ussher et al.   CARDIOVASCULAR RESEARCH

Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways

(2008) Kiwon Ban et al.   CIRCULATION

Dipeptidyl peptidase IV inhibitors in diabetes: more than inhibition of glucagon-like peptide-1 metabolism?

(2008) Martin C. Michel et al.   NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function

(2008) Kei Ohnuma et al.   TRENDS IN IMMUNOLOGY

Protective effects of GLP-1 analogues exendin-4 and GLP-1(9–36) amide against ischemia–reperfusion injury in rat heart

(2007) David P. Sonne et al.   REGULATORY PEPTIDES